Total Funding
58
77
Total FundingConvertible Note raised
Growth Score
-1 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
43330
Epigene Labs designs genomics-driven drug for precision oncology.
- Akpeli Nordor: Co-Founder & CEO
- Arthur de Garidel: Co-Founder & COO
About the Company
Over the past couple of decades, the exponential progress of sequencing technologies has allowed an increasing number of cancer patients to benefit from precision oncology. However, the aggregation, analysis, and visualization of the massive amounts of genomic data remain a major challenge for precision oncology expansion.
The Epigene Labs
technology platform enables cancer drug hunters to seamlessly leverage advanced artificial intelligence in transforming genomic data into actionable insights for designing precision oncology approaches.
With R&D in Paris and business development in Boston, Epigene Labs operates in the setting of value-based partnerships with world leading cancer centers and high-profile biotechs.
